51 matches.
New State Legislation Increases Oversight of Health Care Transactions-
New HIPAA Final Rule: Key Changes to Reproductive Health Care Privacy
Workplace Violence in Health Care: Dissecting the Legal Landscape and Implications for Employers-
Navigating the Labyrinth of Private Equity Investments in Health Care
-
The DEA Is Knocking at Your Door . . . Are You Prepared?
-
The Future of Laboratory Testing Just Got a Little Clearer: FDA's Final Rule on LDTs
-
Down Goes Chevron: A 40-Year Precedent Overturned by the Supreme Court
-
If Cannabis Is Reclassified, What Will Happen to the Marketplace?
-
Unveiling Gender-Affirming Care: Why It Matters and What’s at Stake
-
FDA Releases Laboratory-Developed Tests Final Rule
Spilling Secrets: Navigating Physician Non-Compete Litigation-
Key Changes in Finalized Antitrust Merger Guidelines
-
Braidwood v. Becerra: Challenging the Affordable Care Act’s Preventive Services Coverage Provision
-
Spilling Secrets: Latest Developments – Restrictive Covenants in the Health Care Industry
-
Health Equity: Behind the Buzzwords
-
Telehealth Post-Public Health Emergency: What to Expect in 2024
-
Dietary Supplements: Navigating the Regulatory Maze
-
Game-Changing IRA: Revolutionizing Prescription Drug Pricing and Medicare Benefits
-
Direct Access Laboratory Testing: Future FDA Proposed Regulations on LDTs
-
Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now?
-
Post-Dobbs: One Year Later
-
Managing Trade Secrets and Restrictive Covenants in Health Care M&A Deals
-
Spilling Secrets: How to Secure Key Employees in Health Care M&A Transactions
-
The Legal Battle Over Mifepristone
-
Inflation Reduction Act’s Drug Price Negotiation Provisions – What’s Next?
-
Direct Access Laboratory Testing: Physician Orders and Specimen Collection
-
Legal and Regulatory Landscape for Psychedelics as Therapies
-
2023 Deal Cycle: Considerations for Transactions in Uncertain Economic Times
-
The End of the Public Health Emergency – What’s to Come?
-
Direct Access Laboratory Testing: Reimbursement & Compliance
-
Direct Access Laboratory Testing: Navigating the Regulatory Landscape
-
Unpacking FDA's Final Clinical Decision Support Guidance
-
Post-Dobbs: Considerations for Clinical Trials and Research
-
Post-Dobbs: Access to Reproductive Health Care and Abortion-Inducing Drugs
-
Post-Dobbs: Navigating the Fast-Changing and Uncertain Legal Landscape
-
Health Care's Past, Present, and Future
-
Hot Areas in COVID-19 Enforcement, Testing, and Funding
-
Interoperability: Information Blocking Claims and Enforcement
-
Impact of COVID-19 on Pharmacist Scope of Practice: Before and After the PREP Act
-
Interoperability: Health Care's Next Disruptor Is openEHR
-
Interoperability: A New Vision Through openEHR
-
Entrepreneurship in Biotech: Growing Your Business
-
Interoperability: The Role of Health Information Exchanges
-
Interoperability: The Provider Perspective
-
Chevron Deference: Is It Time for Change?
-
Interoperability: How Far We’ve Come and Where We’re Going
-
No Surprises Act: New Rules and Guidance for Stakeholders (Part 2)
-
No Surprises Act: New Rules and Guidance for Stakeholders (Part 1)
-
Getting Ready for the No Surprises Act
-
How Will Biden’s Executive Order Impact Future Hospital Mergers?
-
What Is the Future of the Acute Care Hospital Industry?
